PMID- 25932245
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150501
LR  - 20201001
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 2
DP  - 2015
TI  - Lipocalin-2 plasmatic levels are reduced in patients with long-term type 2 
      diabetes mellitus.
PG  - 2853-9
AB  - BACKGROUND: De-regulation of adipocytokines synthesis and secretion appears to be 
      involved in the pathogenesis of different metabolic diseases. AIMS: We assessed a 
      possible association between plasmatic levels of lipocalin-2 (LCN2) and type 2 
      diabetes mellitus (T2DM), as well as among levels of LCN2 and those of 
      adiponectin, ghrelin, leptin and resistin, in Mexican diabetic patients. SUBJECTS 
      AND METHODS: Fifty-three healthy individuals and fifty-three with long-term T2DM 
      were included. Measurements from all patients for BMI, fasting glucose, insulin, 
      lipids and adipocytokine profiles were obtained. RESULTS: Comparison of data 
      between the corresponding for diabetic subjects and those of healthy individuals 
      showed significant differences in every anthropometric and metabolic parameter 
      analyzed (P < 0.001). In diabetic subjects, lipocalin-2 and ghrelin plasmatic 
      levels were statistically diminished (P < 0.001) in comparison with the levels 
      registered in healthy subjects. In conclusion, in this study we found that LCN2 
      plasmatic levels are reduced in Mexican subjects with long-term diabetes and this 
      reduction in circulating concentrations is similar to the one reported for 
      anti-inflammatory adipocytokines, which suggests that lipocalin-2 is somehow 
      involved in insulin resistance and cardiometabolic alterations through an 
      uncharacterized mechanism generated by the inflammation process.
FAU - De la Chesnaye, Elsa
AU  - De la Chesnaye E
AD  - Cardiovascular and Metabolic Diseases Research Unit, National Medical Center, 
      Instituto Mexicano del Seguro Social Mexico.
FAU - Manuel-Apolinar, Leticia
AU  - Manuel-Apolinar L
AD  - Endocrine Research Unit, National Medical Center, Instituto Mexicano del Seguro 
      Social Mexico.
FAU - Zarate, Arturo
AU  - Zarate A
AD  - Endocrine Research Unit, National Medical Center, Instituto Mexicano del Seguro 
      Social Mexico.
FAU - Damasio, Leticia
AU  - Damasio L
AD  - Endocrine Research Unit, National Medical Center, Instituto Mexicano del Seguro 
      Social Mexico.
FAU - Espino, Nancy
AU  - Espino N
AD  - Cardiovascular and Metabolic Diseases Research Unit, National Medical Center, 
      Instituto Mexicano del Seguro Social Mexico.
FAU - Revilla-Monsalve, Maria Cristina
AU  - Revilla-Monsalve MC
AD  - Cardiovascular and Metabolic Diseases Research Unit, National Medical Center, 
      Instituto Mexicano del Seguro Social Mexico.
FAU - Islas-Andrade, Sergio
AU  - Islas-Andrade S
AD  - Cardiovascular and Metabolic Diseases Research Unit, National Medical Center, 
      Instituto Mexicano del Seguro Social Mexico.
LA  - eng
PT  - Journal Article
DEP - 20150215
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4402892
OTO - NOTNLM
OT  - Lipocalin-2
OT  - adipocytokines
OT  - diabetes
OT  - inflammation
EDAT- 2015/05/02 06:00
MHDA- 2015/05/02 06:01
PMCR- 2015/02/15
CRDT- 2015/05/02 06:00
PHST- 2014/10/08 00:00 [received]
PHST- 2015/01/21 00:00 [accepted]
PHST- 2015/05/02 06:00 [entrez]
PHST- 2015/05/02 06:00 [pubmed]
PHST- 2015/05/02 06:01 [medline]
PHST- 2015/02/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 Feb 15;8(2):2853-9. eCollection 2015.